Literature DB >> 27639686

A Matched Cohort Study of Patients With End-Stage Heart Failure from Anthracycline-Induced Cardiomyopathy Requiring Advanced Cardiac Support.

Garry R Thomas1, Michael A McDonald2, Jennifer Day3, Heather J Ross2, Diego H Delgado2, Filio Billia2, Jagdish W Butany4, Vivek Rao3, Eitan Amir5, Philippe L Bedard6, Paaladinesh Thavendiranathan7.   

Abstract

Anthracycline-induced cardiomyopathy (AIC) may progress to end-stage heart failure requiring mechanical circulatory support or orthotopic heart transplantation (OHT). Previous studies have described important clinical differences between AIC and nonischemic cardiomyopathy (NIC) cohorts requiring these advanced interventions. Therefore, we sought to extend this literature by comparing echocardiographic parameters, treatment strategies, and the prognosis between matched patients from these cohorts. This is a retrospective matched cohort study. All patients who received a ventricular assist device or OHT at a large Canadian center were reviewed (n = 421; 1988 to 2015) and subjects with clinical and pathologic evidence of AIC were included (n = 17, 4.0%). A comparison cohort with idiopathic NIC from the same database, matched 3:1 for age, gender, ethnicity, and year of heart failure onset was selected. The Mann-Whitney rank-sum and Fisher's exact tests were used for comparisons. Patients with AIC were predominantly women (70.6%) with heart failure diagnosed at age 40.2 ± 15.8 and 8.3 ± 8.9 years after anthracycline treatment. Compared with NIC, no differences were seen in co-morbidities, echocardiographic measures, the proportion of patients receiving a defibrillator, ventricular assist device, or OHT, the incidence of graft failure, and all-cause mortality. In contrast to other studies, AIC was not associated with a higher incidence of right ventricular dysfunction. A greater proportion of patients with AIC developed cancer (recurrence or new primary) post-OHT (21.4% vs 2.3%, p = 0.042). In conclusion, we demonstrate that when matched cohorts of patients with end-stage heart failure secondary to AIC and idiopathic NIC are compared, they are similar with respect to co-morbidities, degree of ventricular dysfunction, and advanced therapeutics used. The prognosis with OHT is also similar.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27639686     DOI: 10.1016/j.amjcard.2016.08.020

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  4 in total

Review 1.  Heart transplantation in survivors of childhood cancer.

Authors:  Svetlana B Shugh; Thomas D Ryan
Journal:  Transl Pediatr       Date:  2019-10

2.  Cardiovascular phenotype and prognosis of patients with heart failure induced by cancer therapy.

Authors:  Wilson Nadruz; Erin West; Morten Sengeløv; Gabriela L Grove; Mário Santos; John D Groarke; Daniel E Forman; Brian Claggett; Hicham Skali; Anju Nohria; Amil M Shah
Journal:  Heart       Date:  2018-05-15       Impact factor: 5.994

Review 3.  Current State of Pediatric Cardio-Oncology: A Review.

Authors:  Molly Brickler; Alexander Raskin; Thomas D Ryan
Journal:  Children (Basel)       Date:  2022-01-19

4.  Characteristics and Outcomes of Women Developing Heart Failure After Early Stage Breast Cancer Chemotherapy: A Population-Based Matched Cohort Study.

Authors:  Husam Abdel-Qadir; Felicia Tai; Ruth Croxford; Peter C Austin; Eitan Amir; Oscar Calvillo-Argüelles; Heather Ross; Douglas S Lee; Paaladinesh Thavendiranathan
Journal:  Circ Heart Fail       Date:  2021-06-30       Impact factor: 8.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.